Medical Condition News

RSS

Diabetes disease management program helps Medicare patients reduce cost of medical care: Study

Medicare patients with diabetes and cardiovascular disease can significantly reduce both the cost of their medical care and rates of hospitalization by participating in a telephone-based diabetes disease management program, a new study finds. The authors will present their results Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

FDA approves NAMENDA XR for treatment of Alzheimer's type dementia

Forest Laboratories, Inc. and Merz Pharmaceuticals GmbH announced today that NAMENDA XR(TM) (memantine hydrochloride) was approved by the U.S. Food and Drug Administration for the treatment of moderate to severe dementia of the Alzheimer's type. NAMENDA XR is a 28 mg once-daily extended-release formulation of NAMENDA.

22 Jun 2010

Asthmatics to suffer more this winter warn experts

Asthma sufferers in Australia have been warned about a bad cold and flu season ahead. 58 percent of the susceptible population is already experiencing asthma attacks since the start of the season according to The National Asthma Council Australia (NACA) on Monday. They went on to say that nearly half of this population is still not vaccinated against seasonal flu.

21 Jun 2010

Gastric bypass surgery improves insulin sensitivity in Type 2 diabetes patients

Gastric bypass surgery improves Type 2 diabetes by other mechanisms in addition to weight loss and does so better than a low-calorie diet despite achieving equal weight loss, a new study finds. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Angeion launches new TRUcal resting metabolic rate system

Angeion Corporation announced that it has launched its new TRUcal™ resting metabolic rate system. Part of its New Leaf® product line, TRUcal includes an analyzer that gently measures one's breath for oxygen and carbon dioxide which gives consumers their true individualized daily calories their body requires. The TRUcal™ system also includes a compact netbook with Bluetooth® technology, adding the benefit of wireless connectivity.

21 Jun 2010

Sinapis initiates dosing in Phase I trial of intravenous infusion of methamphetamine

Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.

21 Jun 2010

Positron sells four Attrius PET scanners

Positron Corporation, a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology, announces the sales of four Attrius™ PET scanners to prominent cardiology practices and orders six Attrius™ PET scanners from its joint venture, Neusoft Positron Medical Systems for immediate delivery.

21 Jun 2010

Experimental cure for Type 1 diabetes

Researchers have developed an experimental cure for Type 1 diabetes, a disease that affects about one in every 400 to 600 children and adolescents. They will present their results in a mouse model of Type 1 diabetes on Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Boston Scientific adds 22 new balloon sizes to PolarCath Peripheral Dilatation System

Boston Scientific Corporation today announced that 22 new balloon sizes have been added to the PolarCath® Peripheral Dilatation System, including balloon lengths of 120 and 150 mm. The PolarCath System is used to restore blood flow in patients with critical limb ischemia (severe blockages in the arteries below the knee) and blockages in the femoral and popliteal (behind the knee) arteries. Both conditions result from peripheral artery disease.

21 Jun 2010

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

One of the leading cancer centers in the Middle East has become among the first in the region to introduce fast and efficient RapidArc® radiotherapy treatments from Varian Medical Systems. Al Amal Hospital in Doha, Qatar, has treated nine brain cancer, prostate cancer and head & neck cancer patients with RapidArc since commencing treatments in early May, and it now plans to roll out the technology for many more indications.

21 Jun 2010

"Lap Band" weight loss surgery improves physical, psychological health in extremely obese adults

One year after weight loss surgery with laparoscopic gastric banding, extremely obese adults demonstrate not only better physical health but also improved psychological health, a new study shows. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications

Palatin Technologies, Inc. today announced results of preclinical studies in respiratory tissue with PL-3994. In rat, guinea pig and human tissues, PL-3994 produced potent relaxation of isolated airway smooth muscle, indicating that PL-3994 may be a potent bronchodilator in humans.

21 Jun 2010

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Dako, a Danish-based world leader in tissue-based cancer diagnostics, and Omnyx, a leader in digital pathology solutions, announced today that they have entered into a three-year agreement to develop clinical algorithms for digital pathology. The aim is to support pathologists in generating even more accurate, objective and reproducible diagnostic results.

21 Jun 2010

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

FDA grants Pathway 510(k) clearance for JETSTREAM G3 SF peripheral revascularization catheter for PVD

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced that the U.S. Food & Drug Administration (FDA) has granted the company 510(k) clearance to market JETSTREAM G3™ SF (Small Fixed), the newest version of its peripheral revascularization catheter for the treatment of PVD.

21 Jun 2010

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

Kowa Pharmaceuticals America, Inc., and Eli Lilly and Company today announced that LIVALO® (pitavastatin) tablets is now available in retail pharmacies throughout the United States. LIVALO, a statin medication approved by the U.S. Food and Drug Administration (FDA) in August 2009 is indicated for adults as an adjunctive therapy to diet for the treatment of primary hyperlipidemia or mixed dyslipidemia. LIVALO is available in doses of 1 mg, 2 mg and 4 mg.

21 Jun 2010

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma.

21 Jun 2010

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Immunomedics Inc. today announced that clinical trial results from the Phase IIb EMBLEM study of epratuzumab, a monoclonal antibody targeting CD22, in patients with moderate-severe systemic lupus erythematosus were presented at the 2010 annual Congress of the European League Against Rheumatism in Rome, Italy.

21 Jun 2010

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, was presented yesterday at the 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which is held through June 22, 2010 at the San Diego Convention Center in San Diego, California.

21 Jun 2010

PHCG recognized with CEO Cancer Gold Standard accreditation in fight against cancer

Publicis Healthcare Communications Group, the world's largest healthcare communications group, has received CEO Cancer Gold Standard accreditation, recognizing the organization's commitment to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.

21 Jun 2010

Medical Condition News

Diabetes disease management program helps Medicare patients reduce cost of medical care: Study

FDA approves NAMENDA XR for treatment of Alzheimer's type dementia

Asthmatics to suffer more this winter warn experts

Gastric bypass surgery improves insulin sensitivity in Type 2 diabetes patients

Angeion launches new TRUcal resting metabolic rate system

Sinapis initiates dosing in Phase I trial of intravenous infusion of methamphetamine

Positron sells four Attrius PET scanners

Experimental cure for Type 1 diabetes

Boston Scientific adds 22 new balloon sizes to PolarCath Peripheral Dilatation System

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

"Lap Band" weight loss surgery improves physical, psychological health in extremely obese adults

Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

FDA grants Pathway 510(k) clearance for JETSTREAM G3 SF peripheral revascularization catheter for PVD

LIVALO for primary hyperlipidemia or mixed dyslipidemia now available in U.S.

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

PHCG recognized with CEO Cancer Gold Standard accreditation in fight against cancer

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News